RxDoctor Payments Data

Jashdeep Dhoot, MD

Clinical Cardiac Electrophysiology · Torrance, CANPI 1417109067

Payments from drug & device makers

$19,874in general payments, 2019–2025

Across 382 payments — averaging $52.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$8K
  • Medtronic$4K
  • Wilson Cook Medical Incorporated$980
  • Boston Scientific$788
  • Biosense Webster, Inc.$782
  • Pfizer$563
  • plus $5K from 33 others

What the payments were for

  • Consulting fees$5,15626%
  • Speaking & faculty fees$1,4807%
  • Travel & lodging$2,68614%
  • Food & beverage$10,27552%
  • Education$2771%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,874 in reported general payments places this provider in the 30th percentile of 290 clinical cardiac electrophysiology providers in California.

See all clinical cardiac electrophysiology providers in California

Medicare billing

Part B allowed, 2024
$463,972
Medicare patients
805
Services billed
4,174

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban371$477,294
XareltoRivaroxaban137$181,626
EntrestoSacubitril/Valsartan56$64,072
FarxigaDapagliflozin Propanediol37$41,710
JardianceEmpagliflozin21$27,778
Repatha PushtronexEvolocumab12$9,595
Flecainide Acetate162$7,450
Metoprolol Succinate365$6,264
Atorvastatin Calcium286$3,190
Losartan Potassium212$2,803
SotalolSotalol Hcl86$1,760
Amiodarone Hcl29$1,730
Digoxin45$1,683
Potassium Chloride46$1,324
Carvedilol98$1,231

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$563$477,294371 claims
Johnson & JohnsonXarelto$275$181,626137 claims
NovartisEntresto$514$64,07256 claims
AstraZenecaFarxiga$445$41,71037 claims
Boehringer IngelheimJardiance$165$27,77821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 290 clinical cardiac electrophysiology providers in California.

Other clinical cardiac electrophysiology in Torrance

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →